Results 161 to 170 of about 5,123 (202)
Some of the next articles are maybe not open access.
Drugs, 2001
Darbepoetin alfa is a novel erythropoiesis-stimulating protein developed for the treatment of anaemia associated with chronic kidney disease. In single-dose studies in patients undergoing dialysis, the mean terminal half-life for intravenous darbepoetin alfa was approximately 3-fold longer than for intravenous recombinant human erythropoitin (r-HuEPO ...
T, Ibbotson, K L, Goa
+9 more sources
Darbepoetin alfa is a novel erythropoiesis-stimulating protein developed for the treatment of anaemia associated with chronic kidney disease. In single-dose studies in patients undergoing dialysis, the mean terminal half-life for intravenous darbepoetin alfa was approximately 3-fold longer than for intravenous recombinant human erythropoitin (r-HuEPO ...
T, Ibbotson, K L, Goa
+9 more sources
Hospital Pharmacy, 2002
Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +3 more sources
Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada +2 more
openaire +3 more sources
Clinical and economic comparison of epoetin alfa and darbepoetin alfa
Current Medical Research and Opinion, 2004The pharmacoeconomics of erythropoietic therapy for the treatment of anemia is receiving renewed attention due to the current availability of two agents. Epoetin alfa has been the standard of therapy for patients with renal disease and cancer-related anemia for more than a decade.
Anthony, Morreale +4 more
openaire +2 more sources
Darbepoetin Alfa in Systolic Heart Failure
New England Journal of Medicine, 20131. Health homes for enrollees with chronic conditions. Document 10-024. Baltimore: Center for Medicare and Medicaid Services, November 16, 2010 (http://downloads.cms.gov/cmsgov/ archived-downloads/SMDL/downloads/SMD10024.pdf). 2. Primary and behavioral health integration grants.
Dimitrios, Farmakis +2 more
openaire +5 more sources
Darbepoetin Alfa and History of Thromboembolic Events
Journal of Clinical Oncology, 2009TO THE EDITOR: In their pooled analysis of individual patientlevel data from all randomized double-blind placebo-controlled trials in patients with chemotherapy-induced anemia receiving darbopoetin alfa or placebo, Ludwig et al do not report whether the proportion of patients with a history of thromboembolic events was well balanced between the two ...
Ferretti G., Felici A., Cognetti F.
openaire +1 more source
An Overview of the Pharmacokinetic Disposition of Darbepoetin alfa
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002Darbepoetin alfa is a new erythropoiesis‐stimulating protein that has five carbohydrate chains compared with three in recombinant human erythropoietin (r‐HuEPO, epoetin alfa). Owing to its increased carbohydrate content, the terminal half‐life of darbepoetin alfa is 2–3‐fold greater than that of r‐HuEPO in patients with chronic kidney disease or cancer.
William C, Zamboni, Clinton E, Stewart
openaire +2 more sources
Darbepoetin alfa for anemia with myelodysplastic syndrome
Expert Review of Hematology, 2015The myelodysplastic syndromes are characterized by refractory cytopenias that lead to symptomatic anemia, bleeding, and increased risk for infections. For almost two decades, the use of darbepoetin and other erythropoietin stimulating agents to treat symptomatic anemia in lower-risk myelodysplastic syndromes has been a standard of care.
David J, Seastone, Aaron T, Gerds
openaire +2 more sources